Comparative Pharmacology
Head-to-head clinical analysis: ECONAZOLE NITRATE versus SPECTAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECONAZOLE NITRATE versus SPECTAZOLE.
ECONAZOLE NITRATE vs SPECTAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing cell membrane permeability.
Topical: Apply a thin layer to affected area twice daily (morning and evening). Vaginal: One applicatorful (150 mg) intravaginally at bedtime for 3 days. Rectal candidiasis: One 150 mg suppository rectally at bedtime for 3 days.
Apply a thin layer to affected area once daily for 4-4 weeks; duration depends on indication.
None Documented
None Documented
Terminal elimination half-life approximately 8-10 hours; clinical relevance: supports twice-daily topical dosing for sustained antifungal effect.
Terminal elimination half-life is approximately 24-30 hours in patients with normal renal function, allowing once-daily dosing.
Primarily hepatic metabolism; <1% unchanged in urine; 30-45% in feces as metabolites; minimal biliary excretion.
Primarily renal: approximately 70% of an oral dose is excreted unchanged in urine; biliary/fecal excretion accounts for ~20%, with the remainder as metabolites.
Category A/B
Category C
Antifungal
Antifungal